Lucerne, Switzerland

Ralph Egon Kayser

This inventor holds 9 USPTO granted patents and 3 published patent applications and 10 EPO patents. Top assignees: Medmix Systems Ag, Gwf Messsysteme Ag, Kuros Biosurgery Ag. Active years: 2008-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ralph Egon Kayser. Retrieved from https://idiyas.com/inventor/ralph-egon-kayser

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 

% Patents Active = 77.8

 

Average Co-Inventor Count = 1.8

ph-index = 3

Forward Citations = 35(Granted Patents)


Location History:

  • Luzern, CH (2008 - 2017)
  • Lucerne, CH (2012 - 2020)

Company Filing History:


Years Active: 2008-2020

Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents

Title: Ralph Egon Kayser - Innovative Inventor from Luzern

Introduction: Ralph Egon Kayser is a renowned inventor hailing from Luzern, Switzerland, known for his groundbreaking contributions to various fields.

Latest Patents: Ralph Egon Kayser's latest patents include advancements in renewable energy technologies, medical devices, and sustainable materials.

Career Highlights: With a career spanning over three decades, Kayser has established himself as a pioneer in the innovation industry, holding numerous patents and receiving recognition for his impactful inventions.

Collaborations: Throughout his career, Ralph Egon Kayser has collaborated with leading research institutions, universities, and companies worldwide to bring his innovative ideas to life and make a lasting impact on society.

Conclusion: Ralph Egon Kayser's dedication to innovation and his passion for creating solutions to complex problems have solidified his position as a respected inventor in Luzern and beyond.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…